参考文献/References:
[1] Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus[J].Diabetes,2009,58(4):773-795. DOI:10.2337/db09-9028.
[2] Zoch ML, Clemens TL, Riddle RC. New insights into the biology of osteocalcin[J].Bone,2016,82:42-49. DOI:10.1016/j.bone.2015.05.046.
[3] Lenders CM, Lee PD, Feldman HA, et al. A cross-sectional study of osteocalcin and body fat measures among obese adolescents[J].Obesity(Silver Spring),2013,21(4):808-814. DOI:10.1002/oby.20131.
[4] Bao Y, Ma X, Yang R, et al. Inverse relationship between serum osteocalcin levels and visceral fat area in Chinese men[J]. J Clin Endocrinol Metab,2013,98(1):345-351. DOI:10.1210/jc.2012-2906.
[5] Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton[J].Cell,2007,130(3):456-469. DOI:10.1016/j.cell.2007.05.047.
[6] Ferron M, McKee MD, Levine RL,et al. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice[J].Bone,2012,50(2):568-575. DOI:10.1016/j.bone.2011.04.017.
[7] Dou J, Ma X, Fang Q, et al. Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in Chinese men[J].Clin Exp Pharmacol Physiol,2013,40(4):282-288. DOI:10.1111/1440-1681.12063.
[8] Aller R, Castrillon JL, de Luis DA,et al. Relation of osteocalcin with insulin resistance and histopathological changes of non alcoholicfatty liver disease[J].Ann Hepatol,2011,10(1):50-55.
[9] Zhou B, Li H, Xu L,et al. Osteocalcin reverses endoplasmic reticulum stress and improves impaired insulin sensitivity secondary to diet-induced obesity through nuclear factor-κB signaling pathway[J].Endocrinology,2013,154(3):1055-1068. DOI:10.1210/en.2012-2144.
[10] Du J, Zhang M, Lu J, et al. Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK[J].Endocrine,2016,53(3):701-709. DOI:10.1007/s12020-016-0926-5.
[11] Beltrán-Sánchez H, Harhay MO, Harhay MM,et al. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010[J].J Am Coll Cardiol,2013,62(8):697-703. DOI:10.1016/j.jacc.2013.05.064.
[12] Bao Y, Zhou M, Lu Z, et al. Serum levels of osteocalcin are inversely associated with the metabolic syndrome and the severity of coronary artery disease in Chinese men[J].Clin Endocrinol(Oxf),2011,75(2):196-201. DOI:10.1111/j.1365-2265.2011.04065.x.
[13] Lerchbaum E, Schwetz V, Nauck M,et al. Lower bone turnover markers in metabolic syndrome and diabetes: the population-based Study of Health in Pomerania[J].Nutr Metab Cardiovasc Dis,2015,25(5):458-463.DOI:10.1016/j.numecd.2015.02.002.
[14] Jung KY, Kim KM, Ku EJ, et al. Age- and sex-specific association of circulating osteocalcin with dynamic measures of glucose homeostasis[J].Osteoporos Int,2016,27(3):1021-1029. DOI:10.1007/s00198-015-3315-7.
[15] Bao YQ, Zhou M, Zhou J,et al. Relationship between serum osteocalcin and glycaemic variability in type 2 diabetes[J].Clin Exp Pharmacol Physiol,2011,38(1):50-54. DOI:10.1111/j.1440-1681.2010.05463.x.
[16] Díaz-López A, Bulló M, Juanola-Falgarona M,et al. Reduced serum concentrations of carboxylated and undercarboxylated osteocalcin are associated with risk of developing type 2 diabetes mellitus in a high cardiovascular risk population: a nested case-control study[J].J Clin Endocrinol Metab,2013,98(11):4524-4531. DOI:10.1210/jc.2013-2472.
[17] Hwang YC, Jee JH, Jeong IK,et al. Circulating osteocalcin level is not associated with incident type 2 diabetes in middle-aged male subjects: mean 8.4-year retrospective follow-up study[J].Diabetes Care,2012,35(9):1919-1924. DOI:10.2337/dc11-2471.
[18] Wei J, Ferron M, Clarke CJ,et al. Bone-specific insulin resistance disrupts whole-body glucose home ostasis via decreased osteocalcin activation[J].J Clin Invest,2014,124(4):1-13. DOI:10.1172/JCI72323.
[19] Mizokami A, Yasutake Y, Gao J, et al. Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice[J].PLoS One,2013,8(2):e57375. DOI:10.1371/journal.pone.0057375.
[20] Otani T, Mizokami A, Hayashi Y,et al. Signaling pathway for adiponectin expression in adipocytes by osteocalcin[J].Cell Signal,2015,27(3):532-544. DOI:10.1016/j.cellsig.2014.12.018.
[21] Ferron M, Wei J, Yoshizawa T,et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism[J].Cell,2010,142(2):296-308. DOI:10.1016/j.cell.2010.06.003.
[22] Reyes-Garcia R, Rozas-Moreno P, Jimenez-Moleon JJ, et al. Relationship between serum levels of osteocalcin and atherosclerotic disease in type 2 diabetes[J].Diabetes Metab,2012,38(1):76-81. DOI:10.1016/j.diabet.2011.07.008.
[23] Yamashita T, Okano K, Tsuruta Y, et al. Serum osteocalcin levels are useful as a predictor of cardiovascular events in maintenance hemodialysis patients[J].Int Urol Nephrol,2013,45(1):207-214. DOI:10.1007/s11255-012-0156-6.
[24] Hwang YC, Kang M, Cho IJ,et al. Association between the circulating total osteocalcin level and the development of cardiovascular disease in middle-aged men: a mean 8.7-year longitudinal follow-up study[J].J Atheroscler Thromb,2015,22(2):136-143. DOI:10.5551/jat.25718.
[25] Jung CH, Lee WJ, Hwang JY,et al. The preventive effect of uncarboxylated osteocalcin against free fatty acid-induced endothelial apoptosis through the activation of phosphatidylinositol 3-kinase/Akt signaling pathway[J].Metabolism,2013,62(9):1250-1257. DOI:10.1016/j.metabol.2013.03.005.
[26] Dou J, Li H, Ma X,et al. Osteocalcin attenuates high fat diet-induced impairment of endothelium-dependent relaxation through Akt/eNOS-dependent pathway[J].Cardiovasc Diabetol,2014,13:74. DOI:10.1186/1475-2840-13-74.
相似文献/References:
[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(06):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]顾朋颖,叶山东.骨钙素与动脉粥样硬化关系的研究进展[J].国际内分泌代谢杂志,2014,(03):197.[doi:10.3760/cma.j.issn.1673-4157.2014.03.015]
Gu Pengying*,Ye Shandong..Relationship between osteocalcin and atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(06):197.[doi:10.3760/cma.j.issn.1673-4157.2014.03.015]
[4]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(06):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[5]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制
——2014年美国糖尿病协会“杰出科学成就奖”
演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(06):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[6]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(06):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[7]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(06):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[8]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(06):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[9]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(06):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[10]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(06):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]